The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
https://www.abstractsonline.com/pp8/#!/10828/presentation/10452
Looking at the titles of last year's abstracts held back for presentation, they were all trials that had reached conclusions. I think it will be highly optimistic to assume or hope that Scancell's phase 1 trial in progress would be select for the official press release.
Let's not lose sight of the fact that they may actually be there to talk about what the abstract title describes - the trial design. There may not be any new data or any new RNS. Short term hyping on the hope of an RNS has consistently resulted in a greater slide back than any gain forward.
Vulpes assessment - extremely strong science, need more dedicated commercial experience.
This message board's general consensus - extremely strong science, need more dedicated commercial experience.
Remember that when the doom-mongers tell us this message board knows nothing.
oh ok, so now i get it - you invested on the say so of someone on here.. and lost a bunch of money you couldn't afford. Now you are bitter for not doing your own research and want to blame everyone else?
the first mile stone payment is on genmab product definition. That was disclosed at the AGM. Could be any day. Milestone payments tend to increase at each milestone, so i would imagine this milestone will be for more than the upfront payment.
It would be highly highly unusual for milestone payments to be related to post approval sales afaik. Milestones are typically "development milestones" with royalties on sales.
The original collaboration agreement with Genmab was Sep 2019. Or at least, strongly suspected to be. I'm not sure the company ever fully confirmed Genmab was the 2019 collaborator. Assuming it is though, then the work has been going on for a lot longer than 6 months! Milestone payments sooner rather then later hopefully.
It's generally considered that when selling a biotech asset, the price and the deal reflects the balance of risk for both the buyer and seller. The biotech may look for more money, and the pharma would look to back load the milestones to balance the risk.
Given the amount of assets and possible products in the Scancell pipeline, isn't there an argument for doing a smaller cash-up front deal on one of the glymabs?
£50 million upfront with no milestones or future royalties could transform the security of the business and prevent future dilution. It may feel like giving away an asset, but we are not exactly short of them, and cash in the bank without dilution would provide the market with a lot of confidence.
In the expansion cohorts so far, the majority of people recruited have been Ovarian patients (as per the interim report). These patients won't ever have been on a checkpoint inhibitor as they are not approved for this indication.
The one patient that we know to have responded, has previously disclosed that they were on a CPI prior to starting this trial. Could it be that despite having stopped the CPI we are still seeing some synergistic effect? I don't know how long the effects of the CPI would stay around for, but it could be an explanation.
Sure makes the Combo-therapy arm results more anticipated.